New evidence-based clinical practice guidelines for the prevention, diagnosis, and treatment of Lyme disease have been developed by a multidisciplinary panel led by the Infectious Diseases Society of America, the American Academy of Neurology, and the American College of Rheumatology. Representatives from an additional 12 medical specialties and patients also served on the panel.
The bankruptcy announced today by antibiotic maker Melinta once again highlights the daunting challenges facing research and development of new infection-fighting drugs. Melinta is the second antibiotic company this year forced into bankruptcy because it could not make a sufficient return on its investment in medicines that are urgently needed to protect individual and public health and national security. Melinta’s bankruptcy puts into jeopardy the continued availability of its four antibiotics — lifesaving tools that patients cannot afford to lose given our already limited antibiotic arsenal.
The spending bill passed today is a welcome step forward. Allocations in the bill will strengthen public health and research efforts during the year ahead and will provide critical support for important goals. At the same time, the legislation in its final form also brings inadequate responses to current and urgent challenges with the potential for long-term and costly consequences.
H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act passed by the House of Representatives today introduces critically needed and significant steps to reduce costs and improve access to life-saving therapies for conditions including HIV and hepatitis C. Importantly, the legislation also brings essential resources to combat antibiotic resistance, find and develop new infection fighting drugs and bring them to market. The balanced approach of this legislation will serve patients and public health.
Today’s subcommittee hearing on U.S. preparedness and responses for the 2019-2020 flu season offers an important opportunity to examine and act on gaps and challenges exacerbating the public health threats of seasonal influenza outbreaks.
The Antibiotic Resistance Threats Report released by the U.S. Centers for Disease Prevention and Control today shows that while recent federal investments to combat antibiotic resistance have had meaningful impacts, the continued spread of infections that are not effectively treated by existing medicines pose deadly threats to patients and public health. As physicians and scientists on the front lines of a growing public health crisis, the Infectious Diseases Society of America urges federal policy makers to respond to the report’s warning with investments and commitment to turning the tide of antibiotic resistance.
When people with severe sepsis, an extreme overreaction by the body to a serious infection, come to the emergency room (ER), they require timely, expert care to prevent organ failure and even death. When that care includes the early involvement of an infectious disease (ID) specialist, patient mortality can be reduced by as much as 40 percent, according to a new retrospective, single-center study published in Open Forum Infectious Diseases.
An analysis and related commentary published in Clinical Infectious Diseases today provide in-depth examination of the deplorable and dangerous conditions in U.S. immigrant detention centers where seven children have died in the last 10 months. Together, the articles underscore an urgent imperative repeatedly cited by ours, and other societies of medical professionals, to investigate and remedy violations of human rights and the most basic standards of public health, infection control and medical practice that have been demonstrated in these facilities.
A device designed to improve adherence to outpatient parenteral antimicrobial therapy (OPAT) took top prize at the second IDEA Incubator, a competition showcasing inventions, products and devices to improve patient care for infectious diseases, which takes place during IDWeek.
The continued steep increase in incidence of sexually transmitted diseases reported in the 2018 data released by the U.S. Centers for Disease Control and Prevention Tuesday, is a cause for deep concern about dangerous gaps in our public health infrastructure.
As government, business, and community leaders from around the world gather in New York today for the United Nations Secretary-General’s Climate Action Summit, attention to the immediate and international threats posed by climate change to human health will be critical to achieving the summit’s goals of advancing from words to urgent action.
The Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR) have extended the public comment period for the draft of their joint guidelines for the prevention, diagnosis, and treatment of Lyme disease for an additional 30 days. The deadline to submit comments is now Sept. 9, 2019.
The Infectious Diseases Society of America (IDSA), the American Academy of Neurology (AAN), and the American College of Rheumatology (ACR) have opened a public comment period for the draft of their joint guidelines for the prevention, diagnosis, and treatment of Lyme disease.…